Classification and management of bisphophonates jaw osteonecrosis;Ostéonécrose des maxillaires en rapport avec la prise de bisphosphonates: Que faire?

Revue Medicale Suisse

Volumn 3, Issue 112, 2007, Pages 1322-1331

  Madrid, Carlos ^a   Bouferrache, Kahina ^a   Jaques, Bertrand ^b   Broome, Martin ^b  

^a POLICLINIQUE MÉDICALE UNIVERSITAIRE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISPHOSPHONIC ACID DERIVATIVE; METRONIDAZOLE; ANTINEOPLASTIC AGENT; BONE DENSITY CONSERVATION AGENT;

ANTIBIOTIC THERAPY; BONE INFECTION; BONE NECROSIS; BONE RADIOGRAPHY; CANCER; DISEASE CLASSIFICATION; FRACTURE; HUMAN; JAW OSTEONECROSIS; MEDICAL LITERATURE; NONHUMAN; ORAL SURGERY; OSTEOPOROSIS; PAGET BONE DISEASE; PATIENT CARE; PATIENT CODING; PERIODONTITIS; PROPHYLAXIS; PUBLICATION; REVIEW; RISK ASSESSMENT; TREATMENT INDICATION; TREATMENT PLANNING; CHEMICALLY INDUCED DISORDER; JAW DISEASE; NEOPLASM; OSTEOLYSIS;

ANTINEOPLASTIC AGENTS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; HUMANS; JAW DISEASES; NEOPLASMS; OSTEOLYSIS; OSTEONECROSIS;

EID: 34250710143     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Marx RE. Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws : A growing epidemic. J Oral Maxillofac Surg 2003;61: 1115-7.
2. Capsoni F, Longhi M, Weinstein R. Bisphosphonate-associated osteonecrosis of the jaw : The rheumatologist's role. Arthritis ResTher 2006;8:219-25.
3. Migliorati CA, Schubert MM, Peterson DE, Seneda LM. Bisphosphonate- associated osteonecrosis of mandibular and maxillary bone : An emerging oral complication of supportive cancer therapy. Cancer 2005;104: 83-93.
4. Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol 2005;23:8219-24.
5. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005;90:1897-9.
6. MashibaT, Mori S, Burr DB, et al. The effects of suppressed bone remodeling by bisphosphonates on microdamageaccumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 2005; 23(Suppl.)36-42.
7. Odvina CV, Zerwekh J E, Rao DS, et al. Severely suppressed bone turn over : A potential complication of alendronatetherapy. J Clin Endocrinol Metab 2005;90: 1294-301. Epub 2004 Dec 14.
8. Richer E, Lewis MA, Odvina CV, et al. Reduction in normalized bone elasticity following long-term bisphosphonate treatment as measured by ultrasound critical angle reflectometry. Osteoporos Int 2005;16:1384-92. Epub 2005 Feb 22.
9. Ferretti G, Fabi A, Carlini P, et al. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology 2005;69:35-43. Epub 2005 Aug 2.
10. ** Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws : Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63:1567-75.
11. ** Migliorati CA, Siegel MA, Elting LS. Bisphosphonate- associated osteonecroses : A long-term complication of bisphosphonate treatment Lancet Oncol 2006; 7:508-14. Review. Erratum in : Lancet Oncol 2006;7:533.
12. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-44.
13. Aspenberg P. Osteonecrosis of the jaw : What do bisphosphonates do ? Expert Opin Drug Saf 2006;5:743-5.
14. Assael LA. A time for perspective on bisphosphonates. Journal of oral and maxillofacial surgery 2006;64: 1704-5.
15. Woo SB, Hellstein JW, Kalmar JR. Narrative (corrected) review : Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753-61. Review. Erratum in : Ann Intern Med 2006;145:235.
16. Vannucchi AM, Ficarra G, Antonioli E, Bosi A. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol 2005;128:738.
17. * Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw : Background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102:433-41.
18. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of Bisphosphonates : A review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
19. Melo MD, Obeid G. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy : Strategies for prevention and early recognition. J Am Dent Assoc 2005;136:1675-81.
20. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 2005;182:417-8.
21. Sarathy AP, Bourgeois SL, Goodell G. Bisphosphonate-associated osteonecrosis of the jaws and endodontic treatment : Two case reports. J Endod 2005;31: 835-6.
22. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphophonates. N Engl J Med 2005;353:99-102.
23. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients : Clinical features and risk factors. J Clin Oncol 2006;24:945-52.
24. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates : Incidence and risk factors. J Clin Oncol 2005; 23:8580-7.
25. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma : A single-centre experience in 303 patients. Br J Haematol 2006;134: 620-3.
26. American Academy of Periodontology, www.perio. org/resources-products/ bisphosphonates.htm
27. Food and drug administration, 2005 www.fda.gov/ohrms/dockets/ac/05/ briefing/2005-4095B2_02_ 12Novartis-Zometa-App-11.pdf
28. American dental association council on scientific affairs. Dental management of patients receiving oral bisphosphonate therapy : Expert panel recommendations. J Am Dent Assoc 2006;137:1144-50.
29. Scully C, Madrid C, Bagan J. Dental endosseous implants in patients on bisphosphonate therapy. J Implant Dent 2006;15:212-8.
30. Migliorati CA. Bisphosphonate-associated oral osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005;99:135.
31. Bennett CL, Nebeker JR, Lyons EA, et al. The research adverse drug events and reports RADAR project JAMA 2005;293:2131-40.
32. Najm S, Lysistsa S, Carrel JP, et al. Ostéonécrose des maxillaires chez des patients traités par bisphosphonates. Presse Med 200534:1073-7.
33. Bornstein MM, Oberli K, Stauffer E, Buser D. Biphosphonate-associated osteonecrosis of the maxilla. Case report and review of the literature. Schweiz Monatsschr Zahnmed. 2006;116:1035-47.
34. e Congrès de la société française de stomatologie et de chirurgie maxillo-faciale. Besançon, 11-13 octobre 2006.
35. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw : Background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102: 433-41. Epub 2006 Jul 31.
36. Updated recommendations for the prevention, diagnosis and treatment of ostéonécroses of the jaw in cancer patients. Basel : Novartis, 2006.
37. Pires F, Miranda A, Cardoso E, et al. Oral avascular bone necrosis associated with chemotherapy and bisphosphonate therapy. Oral Dis 2005;11:365-9.
38. Nastro E, Musolino C, Allegra A, et al. Bisphosphonate associated ostéonécroses of the jaw in patients with multiple myeloma and breast cancer. Acta Haematol 2007;117:181-7.
39. Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006;81:1047-53.
40. Krueger CD, West PM, Sargent M, et al. Bisphosphonate-induced ostéonécroses of the jaw. Annals Pharmacother 2007;41:276-84.